NasdaqGS:MRNABiotechs
A Look At Moderna (MRNA) Valuation After Positive Five Year Melanoma Vaccine Trial Data
Moderna (MRNA) stock is back in focus after five year follow up data showed its personalized mRNA cancer vaccine intismeran autogene, combined with Keytruda, significantly cut melanoma recurrence and death versus Keytruda alone.
See our latest analysis for Moderna.
The positive melanoma data helped drive a 1 day share price return of 7.49% to US$49.06. The year to date share price return of 58.98% sits against a 3 year total shareholder return that is down 60.94%, showing strong recent...